This Is MS Multiple Sclerosis Community: Knowledge & Support

The multiple sclerosis medication fingolimod (Gilenya) led to "rapid and sustained" reductions in MRI-documented inflammatory lesion activity, researchers reported.

In a two-year randomized trial, the medication also slowed the rate of brain volume loss compared with placebo, according to Ernst-Wilhelm Radue, MD, of University Hospital Basel in Basel, Switzerland, and colleagues.

Changes in lesion volume over time also favoured the medication rather than placebo, Radue and colleagues reported online in Archives of Neurology.

Combined with previously reported improvements in relapse rates and disability progression, the findings suggest that the drug -- a sphingosine 1–phosphate receptor (S1PR) modulator -- has a "positive impact on long-term disease evolution," the researchers argued....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1309/

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis